Form 4: IN8BIO Executive Lawrence Lamb Amends Warrant Terms

Lawrence Lamb, EVP and CSO of IN8BIO, INC., amended the terms of outstanding Series B warrants, reducing the exercise price from $1.50 to $0.45 per share.

Summary

• Lawrence Lamb, the EVP and CSO of IN8BIO, INC., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports an amendment to outstanding Series B warrants held by Lamb.
• The exercise price of the warrants was reduced from $1.50 to $0.45 per share on April 27, 2025.
• The warrants were originally granted on December 13, 2023.
• Lamb holds 1,639 Series B warrants with the amended exercise price.
• The warrants are fully vested and exercisable with an expiration date of December 13, 2028.
• The reported securities are included within 1,639 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a warrant amendment. It doesn't inherently convey positive or negative sentiment.

Industry Context

Warrant amendments are not uncommon, especially for smaller biotech companies. They can be used to incentivize executives or to adjust capital structures.

Stakeholder Impact

• The warrant amendment could potentially dilute existing shareholders if the warrants are exercised.
• The reduced exercise price may incentivize the executive to improve company performance.

Key Dates

Keywords

IN8BIO, Lawrence Lamb, Series B Warrants, Warrant Amendment, Beneficial Ownership, Form 4, Executive Compensation